A detailed history of Y Intercept (Hong Kong) LTD transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 89,352 shares of BCRX stock, worth $753,237. This represents 0.03% of its overall portfolio holdings.

Number of Shares
89,352
Holding current value
$753,237
% of portfolio
0.03%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $369,023 - $606,700
89,352 New
89,352 $552,000
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $306,873 - $415,009
-29,226 Closed
0 $0
Q3 2022

Feb 14, 2023

BUY
$10.79 - $14.81 $315,348 - $432,837
29,226 New
29,226 $368,000
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $127,645 - $218,189
-11,042 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $123,449 - $170,709
11,042 New
11,042 $153,000
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $152,572 - $189,508
-10,737 Closed
0 $0
Q2 2021

Aug 26, 2021

BUY
$9.5 - $17.24 $102,001 - $185,105
10,737 New
10,737 $170,000
Q1 2021

May 12, 2021

SELL
$7.37 - $13.61 $92,707 - $171,200
-12,579 Closed
0 $0
Q4 2020

Feb 05, 2021

BUY
$3.37 - $8.61 $42,391 - $108,305
12,579 New
12,579 $94,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.